A key part of what makes Y-mAbs Therapeutics’ two-step bispecific fusion protein and radiotherapeutic effective comes down to concentration.

Big pharma and investors are piling into the precision radiation space as the next generation of increasingly potent targeted α-particle therapies promises to destroy cancerous cells with minimum damage to healthy tissues.

CAMP4 is currently working on CMP-CPS-001, a novel investigational therapy designed to address the underlying cause of UCDs by regulating genes associated with the condition. The first clinical trial of this program was initiated in March 2024 with a phase 1 single-ascending dose study in healthy volunteers. Following the completion of this trial, a multiple-ascending dose study was initiated.

Rex’s company, F2G, is in the final stages of clinical trials for an antifungal drug called olorofim. This drug prevents fungi from making pyrimidines, a type of building block for DNA and RNA. Interfering in that process prevents fungi from replicating and can kill some dangerous fungi, including Aspergillus species. If the drug is approved by the U.S. Food and Drug Administration, it will have been about a 25-year journey.

Harbinger Health is advancing a blood-based screening platform initially focused on pancreatic and biliary cancers – two of the deadliest malignancies that currently lack effective screening programs and are often…

Innovation in pharma isn’t just about molecules and machinery; it’s powered by people. Visionaries, disruptors, and dedicated minds drive the next wave of medicine, transforming bold ideas into life-changing therapies for patients around the world.

In this episode of In Combination, host Tom von Gunden combines the perspectives of three executives at Revolo Biotherapeutics – CEO Woody Bryan,

MindMed recently announced that the first patient has been dosed in its phase 3 Emerge study evaluating MM120 ODT for treatment of major depressive disorder (MDD). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD).